Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Gala Health vs StackMD

Gala Health
Graded #17

Higher grade

vs+19.500000000000007
StackMD
Graded #258

Lower grade

The verdict

Gala Health takes it — 82.9/100 to 63.4/100.

Gala Health grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. A compounded tirzepatide and semaglutide program for women that reaches all 50 states and keeps a brand-name Ozempic path open — but its $179 and $149 headline rates are yearly-subscription prices, not monthly ones.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueGala Health +38
84
46
Dose & formulationGala Health +29
83
54
Clinical oversightGala Health +7
85
78
Labs & monitoringGala Health +21
83
62
FulfillmentStackMD +1
88
89
Contract termsStackMD +3
66
69
Gala Health · left barStackMD · right bar

The numbers

MetricGala HealthStackMD
WeighScore82.9/10063.4/100
GradeB−C
Scorecard rank#17#258
SemaglutideNot disclosed$125/mo (1 mg dose, plus a separate fee, compounded)
Tirzepatide$179/mo (yearly subscription)$199/mo (5 mg dose, compounded)
CoverageAll 50 statesAll 50 states
Brand-name accessYesCompounded only
Oral / sublingualInjection onlyInjection only
Gala Health

Graded #17 · B−

Strengths

  • Low compounded entry if you prepay the year — $179/mo tirzepatide and $149/mo microdose on the yearly subscription, $199/mo on a 3-month plan
  • Prices are published openly rather than quiz-gated, with all doses included at the one rate
  • All 50 states and LegitScript-verified, with a brand-name Ozempic path kept open ($1,299)
  • HRT and menopause care available alongside GLP-1

Where it loses points

  • No month-to-month price is published anywhere — the $179 tirzepatide and $149 microdose rates are both yearly subscriptions, and the shortest term Gala names is a 3-month plan at $199/mo
  • Compounded formulations are not FDA-approved
  • Brand-name Ozempic is priced steeply at $1,299
  • No oral or sublingual route offered yet — injection only
  • Newer operator (Gala GLP-1 by AI Coaching Inc) with no named clinicians and no named dispensing pharmacy
StackMD

Graded #258 · C

Strengths

  • Publishes an exact price for every dose strength rather than a single 'from' figure — semaglutide $125-$225, tirzepatide $199-$449
  • Names both its legal entity (Medical 360 HC PLLC) and its prescribing telehealth partner, SamaritanMD
  • No membership or platform fee — the medication price is the whole price
  • States plainly that its compounded medications are 'not FDA-approved and have not been evaluated by the FDA for safety, efficacy, or quality'
  • Telehealth offered in all 50 states per its terms, with free discreet shipping and FSA/HSA eligibility

Where it loses points

  • All sales are final — 'No refunds are issued except as described below', and dispensed medication cannot be returned
  • Compounding pharmacies are never named, only 'a licensed third-party pharmacy'
  • Price rises steeply with dose: tirzepatide runs $199 at 5mg to $449 at 30mg
  • Billing and refunds are handled by SamaritanMD — StackMD 'has no authority to issue refunds' on its behalf
  • Terms impose binding arbitration in New York and waive jury trial and class-action participation

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard